Literature DB >> 23159615

Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.

Saori Odagiri1, Kunikazu Tanji, Fumiaki Mori, Yasuo Miki, Akiyoshi Kakita, Hitoshi Takahashi, Koichi Wakabayashi.   

Abstract

Histone deacetylase 6 (HDAC6) is a multifunctional cytoplasmic protein that plays an especially critical role in the formation of aggresomes, where aggregates of excess protein are deposited. Previous immunohistochemical studies have shown that HDAC6 accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies (DLB) as well as in glial cytoplasmic inclusions in multiple system atrophy (MSA). However, it is uncertain whether the level and activity of HDAC6 are altered in the brains of patients with neurodegenerative dementia. In the present study, we demonstrated that the level of HDAC6 was not altered in the temporal cortex of patients with Alzheimer's disease and DLB in comparison with controls. In contrast, the level of HDAC6 was significantly increased in the temporal cortex of patients with frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) and in the cerebellar white matter of patients with MSA. However, the level of acetylated α-tubulin, one of the substrates of HDAC6, was not altered in FTLD-TDP and MSA relative to controls. These findings suggest that the induced level of HDAC6 in the brain is insufficient for manifestation of its activity in FTLD-TDP and MSA.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159615     DOI: 10.1016/j.bbrc.2012.11.034

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Acetyltransferases (HATs) as targets for neurological therapeutics.

Authors:  Anne Schneider; Snehajyoti Chatterjee; Olivier Bousiges; B Ruthrotha Selvi; Amrutha Swaminathan; Raphaelle Cassel; Frédéric Blanc; Tapas K Kundu; Anne-Laurence Boutillier
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

2.  Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.

Authors:  Janina Leyk; Olaf Goldbaum; Monika Noack; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2014-12-02       Impact factor: 3.444

3.  An acetylation switch controls TDP-43 function and aggregation propensity.

Authors:  Todd J Cohen; Andrew W Hwang; Clark R Restrepo; Chao-Xing Yuan; John Q Trojanowski; Virginia M Y Lee
Journal:  Nat Commun       Date:  2015-01-05       Impact factor: 14.919

Review 4.  Epigenetic studies in Alzheimer's disease: current findings, caveats, and considerations for future studies.

Authors:  Katie Lunnon; Jonathan Mill
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2013-09-13       Impact factor: 3.568

5.  Role of Altered Expression, Activity and Sub-cellular Distribution of Various Histone Deacetylases (HDACs) in Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis.

Authors:  Arpna Srivastava; Jyotirmoy Banerjee; Vivek Dubey; Manjari Tripathi; P Sarat Chandra; M C Sharma; Sanjeev Lalwani; Fouzia Siraj; Ramesh Doddamani; Aparna Banerjee Dixit
Journal:  Cell Mol Neurobiol       Date:  2020-11-28       Impact factor: 5.046

6.  Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice.

Authors:  Tabassum Majid; Deric Griffin; Zachary Criss; Matthew Jarpe; Robia G Pautler
Journal:  Alzheimers Dement (N Y)       Date:  2015-10-11

7.  The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.

Authors:  Sheng-Jun Fan; Fang-I Huang; Jing-Ping Liou; Chia-Ron Yang
Journal:  Cell Death Dis       Date:  2018-05-29       Impact factor: 8.469

Review 8.  Targeting Aggrephagy for the Treatment of Alzheimer's Disease.

Authors:  Sandeep Malampati; Ju-Xian Song; Benjamin Chun-Kit Tong; Anusha Nalluri; Chuan-Bin Yang; Ziying Wang; Sravan Gopalkrishnashetty Sreenivasmurthy; Zhou Zhu; Jia Liu; Chengfu Su; Senthilkumar Krishnamoorthi; Ashok Iyaswamy; King-Ho Cheung; Jia-Hong Lu; And Min Li
Journal:  Cells       Date:  2020-01-28       Impact factor: 6.600

9.  Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain.

Authors:  Michel Koole; Donatienne Van Weehaeghe; Kim Serdons; Marissa Herbots; Christopher Cawthorne; Sofie Celen; Frederick A Schroeder; Jacob M Hooker; Guy Bormans; Jan de Hoon; Janice E Kranz; Koen Van Laere; Tonya M Gilbert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-07-08       Impact factor: 9.236

10.  HDAC6 Interacts With Poly (GA) and Modulates its Accumulation in c9FTD/ALS.

Authors:  Giulia Del Rosso; Yari Carlomagno; Tiffany W Todd; Caroline Y Jones; Mercedes Prudencio; Lillian M Daughrity; Mei Yue; Karen Jansen-West; Jimei Tong; Wei Shao; Yanwei Wu; Monica Castanedes-Casey; Lilia Tabassian; Björn Oskarsson; Karen Ling; Frank Rigo; Dennis W Dickson; Tso-Pang Yao; Leonard Petrucelli; Casey N Cook; Yong Jie Zhang
Journal:  Front Cell Dev Biol       Date:  2022-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.